Dr. Kazmi of Novartis will be president and CEO of jubilant therapeutics Inc., a new innovative biopharmaceutical company in the United States

September 10, 2019 / AP / -- jubilant Life Sciences Limited announced that Syed Kazmi, M.B.A and Ph.D., would join jubilant therapeutics Inc., a new innovative biopharmaceutical company in the United States, as president and CEO Dr Kazmi, from Novartis Pharmaceuticals Corporation, was vice president and head of global cancer business development and licensing Earlier this year, jubilant Life Sciences set up jubilant therapeutics by divesting part of its proprietary innovation assets at different discovery and development stages The new company has a unique business model, which combines the semi virtual model and has significant synergy with other businesses of jubilant Life Sciences, including strategic cooperation with world-class pre clinical cro jubilant BIOSYS The strategy of jubilant therapeutics is to discover and develop new small molecule inhibitors that are mainly used for important oncology goals and previously unavailable goals, and to establish creative cooperation to bring innovative therapies to patients in need The company's current product line includes a new LSD1 / HDAC6 double epigenetic inhibitor for unmet needs of liquid cancers such as acute myeloid leukemia (AML), a small molecule PDL-1 therapy with the same efficacy as macromolecules, but with smaller side effects, which is expected to solve the unmet needs of small molecule PAD4 inhibitors in a variety of automatic epidemic free diseases, as well as Prmt5 inhibitors for lymphoma Shyam bhartia, chairman of jubilant Life Sciences, and Hari bhartia, CO chairman, said: "Syed is warmly welcomed as CEO of jubilant therapeutics Syed has more than 25 years of career in M & A, licensing, strategic cooperation and R & D of professional biotechnology companies and large pharmaceutical companies We believe that his rich experience will help make jubilant therapeutics a successful global clinical stage biopharmaceutical company committed to changing the lives of patients with serious diseases " Syed Kazmi said: "I am honored to serve as CEO, continue to consolidate product assets and cooperation to accelerate the pace of new innovative drugs to market I look forward to turning jubilant therapeutics into a leading biopharmaceutical company " Brief introduction to Jubilant Therapeutics Jubilant Therapeutics Inc., an innovative biopharmaceutical company headquartered in the United States, is a subsidiary of Jubilant Life Sciences Ltd., which is committed to developing breakthrough therapies to treat cancer and other serious diseases For more information, please visit jubilant Life Sciences introduction jubilant Life Sciences Limited is a comprehensive global pharmaceutical and life sciences company engaged in pharmaceutical, life sciences ingredients and other businesses, including drug discovery solutions, Indian branded pharmaceuticals and patent innovation For more information, please visit Source: jubilant therapeutics